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Introduction: Utilization and Efficiency of Secondary prevention therapies
in patients presenting with NSTEMI associated with normal or near-normal
findings on angiography and non-contributory CMR is still unknown
Objectives: The aim of our study is to compare the rates of secondary pre-
vention medication prescription and outcomes in patients with approved isch-
emic cause on cardiac MRI versus patients with non-contributory CMR
Methods: A retrospective monocentric study enrolling all subsequent
patients hospitalized for NSTEMI without significant lesions in coronary
arteries (stenosis < 50%), between January 2004 and January 2010. Patients
were divided into two groups, depending on CMR findings. In the first group,
43 patients with confirmed myocardial infarction and the Group 2 consisted
of 22 non-contributory CMR patients. Patients with confirmed acute myocar-
ditis were excluded from the study. We measured rates of aspirin, statin, β-
blocker, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II
receptor blocker (ARB) prescription at hospital discharge and a mean follow
up of 55 months among eligible patients.
Results: Baseline clinical, electrocardiographic and echographic character-
istics of the patient population were similar between the 2 groups. At hospital
discharge, patients with non-contributory CMR had significantly lower rates
of aspirin (68.1% versus 90.9%, p<0.05), statin (36.3% versus 76.8%,
p<0.001), β-blocker (31.8% versus 64.3%, p<0.001), and ACEI/ARB (36.3%
versus 76.2%, p<0.001) prescription as compared with confirmed
ischemic patients. After a mean follow up of 55 months, patients with non-
contributory CMR remained significantly less likely to receive prescriptions of
secondary prevention therapies compared with the ischemic group (all proba-
bility values <0.0001). MACE (Death, non fatal MI and TLR) was signifi-
cantly higher in the ischemic group (12.2% vs 0%) (p<0.0001).
Conclusion: Our study demonstrates that patients with non-contributory
CMR have an excellent prognosis although they received a lower rate of sec-
ondary prevention medication prescription at hospital discharge and long term
follow up, as compared with patients with confirmed myocardial infarction.
These findings highlight an opportunity to clarify the care of this group.
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Introduction: The pericarditis is an inflammation of the pericardium
accompanied or not by a pericardial effusion. Its etiopathogeny is variable.
Through this work we describe the clinical and paraclinical characteristics of
the pericarditis.
Materials and Methods: it is a retrospective study including 15 patients
hospitalized in our service over a period of seven years from 2006 to 2013,
presenting a pericarditis.
Results: It was of 15 patients including 5 men and 10 women, with a
sex ratio of 0.5. The average age of our patients was 49 years (26 to
83 years). The pericarditis was revealed by: dysphonia (86% of cases), a
chest pain (20% of cases), a flu-like syndrome with a moderate fever (13%
of cases) and edema of the lower limbs (26% of cases). All patients had
ultrasound a pericardial effusion well tolerated (moderate to abundant)
except four patients who were in tamponade. She was of viral origin in
4 cases. It was in relation to a systemic disease in 6 cases: a systemic
lupus erythematosus isolated in 3 cases, a rheumatoid arthritis in one case
and a Sjögren syndrome in one case. In three cases the pericarditis was of
renal origin. In addition, the pericarditis was secondary to radiotherapy for
thymom in one case. In a single patient no etiology has been found.
The evolution under specific medical treatments was good except of
three patients who needed a surgical treatment with transition to chronicity
in two cases.
Conclusion: The pericarditis is often easy to diagnose. A complete eti-
ological investigation allows an earlier and adapted therapeutic. A good
collaboration between an internist and cardiologist would allow an effec-
tive prevention of the acute risk of tamponade and chronic evolution
toward the constriction.
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Estetrol (E4) is a natural estrogen produced by the human fetal liver
only during pregnancy. Its distinctive biological profile offers potential
benefits in women’s health, such as contraception and hormone replace-
ment therapy. The crystal structures of the estrogen receptor α (ERα)
ligand binding domain with 17beta-estradiol (E2) and E4 were very sim-
ilar, whereas these two estrogens showed distinct positioning within phos-
pholipid bilayers. Using in vivo approaches, we demonstrated that high
doses of E4 stimulate genomic, ERα-dependent effects in the uterus
leading to epithelial proliferation and prevent atheroma in hypercholester-
olemic mice to a similar extent as E2. In contrast to E2, however, E4
failed to promote membrane-initiated ERα signaling such as acceleration
of endothelial healing. Moreover, E4 antagonized this endothelial effect of
E2. We conclude that E4 is a weak estrogen able to modulate the nuclear/
transcriptional activity of ERα, and is not only devoid of membrane-initi-
ated steroid signal, but also able to antagonize the membrane effects of E2,
thereby delineating a distinctive profile of ERα activation.
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